1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
Year: 2020
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: M. Sharma, R.E. Sanborn, G.M. Cote, J.C. Bendell, S. Kaul, F. Chen, A. Berezhnoy, P. Moore, E. Bonvini, B.J. Sumrow, J.J. Luke
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Ariad Pharmaceuticals, Celgene, Boston Scientific Corporation, Chordoma Foundation, Regeneron Pharmaceuticals, Merck KGaA, Exelixis, Celldex Therapeutics, Five Prime Therapeutics, Agios Pharmaceuticals, Mersana Therapeutics, Mirati Therapeutics, BeiGene, Incyte, Calithera Biosciences, Innovent Biologics, Apollomics, MacroGenics, Springworks Therapeutics, Eisai, Astellas Pharma, PharmaMar, MorphoSys, Ipsen, Symphogen, Bavarian Nordic, Qbiotics, Genentech, EMD Serono, Cilag
OpenAlex ID: W3088130283